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Summary It is well known that there might be an epidemiological association between Helicobacter pylori infection and extraintestinal diseases. This study aimed at determining H. pylori infection in epileptic patients. Forty-seven cryptogenic epileptic patients (Group 1) and 35 healthy people (Group 2) participated in this study. Presence of H. pylori infection was examined by H. pylori stool antigen (HpSA), H. pylori IgG, and IgM. HpSA was detected in 21 participants (44.6%) in Group 1 and in 3 participants (8.5%) in Group 2. H. pylori IgM was positive in 27 participants (57.4%) in Group 1 and in 8 participants (22.8%) in Group 2. H. pylori IgG was positive in 37 participants (78.7%) in Group 1 and in 13 participants (38%) in Group 2. The difference of rates of HpSA, H. pylori IgM and IgG in Groups 1 and 2 were found statistically significant (x 2 = 4.18, p = 0.04; x 2 = 9.18, p = 0.0017; x 2 = 14.58, p < 0.001, respectively). We also compared presence of H. pylori infection between the epileptic patients with poor and good prognosis; HpSA positivity was detected in 15 (62.5%) of 24 and 6 (26%) of 23, respectively, and the differences were statistically significant (x 2 = 6.30, p = 0.012). H. pylori IgM positivity was detected in 16 (66%) of 24 patients with poor prognosis and 11 (47.8%) of 23 patients with good prognosis ( p > 0.05). H. pylori IgG positivity was detected in 18 (75%) of 24 patients with poor prognosis and 19 (82.6%) of 23 patients with good prognosis. The differences of H. pylori IgM and IgG positivity rates in epileptic patients with poor and good prognosis were not found statistically significant ( p > 0.05). These results suggest a probable association between the acute H. pylori infection and epilepsy, especially with poor prognosis. # 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Introduction
Helicobacter pylori causes chronic infection in a large proportion of the world's population 1 and it is associated with a number of different clinical conditions. These include gastritis, gastric and duodenal ulcers, gastric adenocarcinoma, and mucosaassociated lymphoid tissue lymphoma. 2 Recent studies suggest the possible role of H. pylori infection in extra intestinal diseases, such as thrombocytopenic purpura, iron deficiency anemia, epilepsy, various dermatological disorders, and Alzheimer disease. [3] [4] [5] [6] [7] [8] [9] The cause of H. pylori infection on extra intestinal diseases could be an immunological mechanisms response to either an antigen released during tissue destruction or an infective agent. Mehmet et al. 10 reported that the concentrations of total nitrite and nitrate and cytokines (TNF-alpha, IL-2R, IL-6, and IL-8) in gastric fluids and sera of H. pylori-positive gastric cancer patients were higher than H. pylori-negative control groups. This effect of H. pylori on markers of inflammation, such as fibrinogen and leukocyte count, may be mediated via certain cytokines, including interleukin-6 and tumor necrosis factor (TNF-alpha). Concentrations of this cytokine are increased in the gastric mucosa of H. pylori positive infected patients.
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The brain is a symptom-producing organ, and one of the symptoms due to a basic brain dysfunction is epilepsy. The pathophysiologic background is multifactorial in most epilepsy, as different pre-, peri-, and postnatal triggers or environmental conditions influence one or several genetic factors, where also gender is of importance. One of the genetic factors is immunodysfunction, and the trigger mechanism may be a virus, a parasitic, or a bacterial infection. 3, [12] [13] [14] It has been reported that immunological mechanisms might play a role in the pathogenesis of seizure disorders. 15, 16 This study was conducted to identify the presence of H. pylori infection at epileptic patients and its relationship with poor prognosis.
Materials and methods
In the present study, two populations were compared: Group 1 and Group 2. Group 1 (the experimental group) consisted of 47 cryptogenic epileptic patients. Group 2 (the control group) consisted of 35 healthy people. Epilepsy patients, who attended to the Department of Neurology of Duzce School of Medicine between 2000 and 2004, participated in this study. These epileptic outpatients were contacted during their periodic check ups between January 2000 and June 2004. Epidemiological data determining the socioeconomic status of the Groups 1 and 2 participants were collected by a paper and pencil questionnaire. Clinical records were examined on the history of antiepileptic medication, the time of onset and prognosis, and the type of epileptic syndrome according to The International Classification of Epilepsies and Epileptic Syndromes. A standardized questionnaire for poor prognostic characteristics, medical history (the date of first epileptic attack and the frequency of attacks), and subjective symptoms, was administered to all patients. Patients' socioeconomic levels were characterized using two factors: (a) the average monthly income per person and (b) the living space per person (in square meters) in their residential areas (e.g., homes, apartments and townhouses). Neurological examination for each individual was performed and the physical findings were recorded. Epilepsy with good prognosis, free from seizures for the last 3 years, was taken into consideration. The Ethical Committee of the Abant Izzet Baysal University, Duzce School of Medicine Hospital has approved this study and the informed consent was obtained from the participants prior to the data collection.
Prospective collection of clinical and microbiologic data was obtained from the individuals in Groups 1 and 2. Stool and blood samples were obtained to detect the presence of H. pylori infection. Fecal samples, obtained from both groups, were examined for determination of H. pylori stool antigen. Additionally, blood samples of all participants were tested for determination of H. pylori antibody (IgM and IgG). The stool samples were placed into a tube containing 200 ml of sample diluents and they were stored at (À20 8C) until the assay was performed. The H. pylori stool antigen (HpSA) EIA test (Premier Platinum, Meridien Diagnostis, USA) was used for the detection of the H. pylori antigen from stool samples. H. pylori IgM enzyme-linked immunosorbent assay (ELISA) (Ridascreen H. pylori IgM, r-biopharm, Dormstart, Germany) antibody test, H. pylori IgG ELISA (Ridascreen H. pylori IgG, r-biopharm) antibody test were used for the detection of H. pylori antibody from blood samples.
Statistical analysis
We conducted statistical analysis using SPSS 11.0 for Windows 98. Numerical data were analyzed with Independent Sample t-test. Chi-square and Fisher's exact probability tests were applied for the categorical data. A p-value that is equal to or less than 0.05 was considered statistically significant. Table 3 .
Results
Groups
Based on the questionnaire responses, patients were categorized as their age groups and their epileptic disorder period. Three age groups were crafted: ''10-29'' (n = 20), ''30-49'' (n = 11), and ''50-79'' (n = 16). The rates of HpSA positivity for these age groups were 8 (40%), 7 (63%), and 6 (37.5%), respectively. The rates of anti-H. pylori IgM positivity were 15 (75%), 4 (36.4%), and 8 (50%) and the rates of anti-H. pylori IgG positivity were 14 (70%), 8 (72.7%), 14 (87.5%). The difference between presence of H. pylori infection and age groups of the patients were not found statistically significant (p > 0.05). The characteristics and distributions of the epileptic patients are shown in Table 4 .
The Group 1 participants were grouped into three sub-categories based upon the duration of their epilepsy: ''0-5 years'' (n = 23), ''6-11 years'' (n = 7), and ''12 years and more'' (n = 17). The relationship between the duration of epilepsy and H. pylori infection was examined. The difference between presence of H. pylori infection and duration of the epilepsy was not found statistically significant (p > 0.05). The relationship between the Table 5 .
We also compared the presence of H. pylori infection among the patients with poor prognosis and good prognosis. Of these 47 epileptic patients, 24 (50%) showed poor prognosis and 23 (50%) showed good prognosis. HpSA positivity was detected in 15 (62.5%) of 24 patients with poor prognosis and 6 (26%) of 23 patients with good prognosis. The difference of HpSA positivity rates in epileptic patients with poor and good prognosis was found statistically significant (x 2 = 6.30; p = 0.012). H. pylori IgM positivity was detected in 16 (66%) of 24 patients with poor prognosis and 11 (47.8%) of 23 patients with good prognosis ( p > 0.05). The differences of H. pylori IgM and H. pylori IgG positivity rates in epileptic patients with poor and good prognosis were not found statistically significant. H. pylori IgG positivity was detected in 18 (75%) of 24 patients with poor prognosis and 19 (82.6%) of 23 patients with good prognosis ( p > 0.05). These results were shown in Table 6 .
Discussion
The relationship with extra-intestinal diseases and chronic H. pylori infections is known. This relationship is probably associated with immunological mechanisms. Seizures may be triggered by immunological mechanisms due to H. pylori infections. That immunological mechanisms, which may play a role in the pathogenesis of seizure disorders, was first proposed by Walker. 17 Karpiak et al. 15 studied seizure induction in rats by antibodies against brain gangliosides. Ettlinger and Lowrie 16 put forward the hypothesis that epileptic discharges could be the result of an autoimmune response to either an antigen released during tissue destruction, or an infective agent. Bartolomei et al. 18 found anti-GM1 antibodies in human cryptogenic focal epilepsies, and suggested a new form of immune-mediated epilepsy. Turrin et al. 19 suggest a different mechanism involved in regulating the innate immune reaction in response to seizures and this mechanism could have direct implications for the neuropathology associated with epilepsy. Although pro-inflammatory markers were induced in a different manner across the central nervous system (CNS), their patterns were not characteristic of those caused by other inflammatory challenges, such as endotoxin. Inflammatory signals have also been reported in clinical cases of epilepsy 20 and immune molecules have already been associated with predisposition to epilepsy. 21 Recent studies reported some probable relationships between H. pylori infection and neurological diseases as Alzheimer disease (AD), acute inflammatory demyelinating polyradiculoneuropathy. 9, 22, 23 Kountouras et al. 9 investigated the association between H. pylori infection and AD. They found that the rate of H. pylori infection in AD patients is higher than the ones in control group. They emphasized that H. pylori infection may influence the pathophysiology of AD through one of the following mechanisms: platelet activation, releasing large amounts of pro-inflammatory and vasoactive substances, such as cytokines (interleukin [IL]-1, IL-6, IL-8, IL-10, IL-12, tumor necrosis factoralpha, interferon-gamma), eicosanoids (leukotrienes, prostaglandins catalyzed by cyclooxygenase enzymes), and acute phase proteins (fibrinogen, C-reactive protein), causing the development of cross mimicry between endothelial and Hp antigens., producing reactive oxygen metabolites and circulating lipid peroxides. Okuda et al. 3 investigated the rate of H. pylori infection in epileptic patient and its influence on 150
A. Ozturk et al. prognosis. They found that epileptic patients without H. pylori infection showed good prognosis. They proposed that H. pylori infection, possibly through production by anticardiolipin antibodies, is involved in some cases of epilepsy. In the present study, the presence of H. pylori infection in epileptic patients was investigated for the possible trigger effect of seizure via immunological mechanisms. We preferred non-invasive methods to investigate H. pylori infection. H. pylori antibody (IgM and IgG) from blood samples and HpSA from stool samples were analyzed. Since there is evidence that infected individuals excrete H. pylori in feces, an enzyme immunoassay (EIA, HpSA) has been developed that can detect H. pylori antigen in human feces during active infection. 24 Therefore, it is non-invasive; HpSA immunoassay would be particularly important for patients for whom endoscopy is not clinically indicated. The sensibility and specificity of HpSA are reported 100 and 97%, respectively. 25 In our study, we particularly looked at to the groups of people who were at similar ages and had similar socioeconomic status. The average monthly income and the living space per person in a residential area were considered as factors identifying the socioeconomic status (see Table 2 for details). The t-test analysis revealed that the means of monthly income and the living space for Groups 1 and 2 participants were not significantly different from one another. We compared Groups 1 and 2 based upon the H. pylori infection rate. In Group 1, we observed higher rates of H. pylori infection than the Group 2. HPSA and H. pylori IgM tests were the criteria of active infection and were higher in Group 1 compared to Group 2. The rate of HpSA positivity was higher in patients with poor prognosis rather than good prognosis, demonstrating the influence of poor prognosis. Our findings reveal that H. pylori infections might trigger epilepsy by immunologic mechanisms as also shown in previous studies. Therefore, we suggest that H. pylori infection should be investigated at epileptic patients, especially the patients with poor prognosis. HpSa tests that are easy to run can be used to identify active H. pylori infections at those patients.
However, the relevant studies published so far are few in number and they involve small series of patients. Further studies are needed especially with more participants.
